SRPT Overview

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Wall Street analysts forecast SRPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sarepta Therapeutics Inc revenue for the last quarter amounts to 442.93M USD, decreased -32.73

Sarepta Therapeutics Inc. EPS for the last quarter amounts to -2.70 USD, decreased -304.55

Sarepta Therapeutics Inc (SRPT) has 835 emplpoyees as of March 12 2026.

Today SRPT has the market capitalization of 1.85B USD.